Application
SMCR7L Antibody (N-term) western blot analysis in mouse liver tissue lysates (15ug/lane).This demonstrates the SMCR7L antibody detected SMCR7L protein (arrow).| Product Name | SMCR7L Antibody (N-term) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | SMCR7L; MID51; MIEF1; Mitochondrial dynamic protein MID51; Mitochondrial dynamic protein of 51 kDa; Mitochondrial elongation factor 1; Smith-Magenis syndrome chromosomal region candidate gene 7 protein-like |
| Clonality | Polyclonal |
|---|---|
| Isotype | Ig |
| Host Species | Rabbit |
| Tested Applications | WB |
| WB:1:100~500 |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Gene Synonyms | MID51 MIEF1 |
|---|---|
| Alternative Names | SMCR7L MID51 MIEF1 Mitochondrial dynamic protein MID51 Mitochondrial dynamic protein of 51 kDa Mitochondrial elongation factor 1 Smith-Magenis syndrome chromosomal region candidate gene 7 protein-like |
| Molecular Weight(MW) | 51293 Da |
| Function | Mitochondrial outer membrane protein which regulates mitochondrial morphology. Mitochondrial morphology is controlled by two opposites processes: fusion and fission. Seems to have a key role in inhibiting DNM1L-induced mitochondrial fission |
| Tissue Specificity | Expression is relatively high in heart, skeletal muscle, pancreas and kidney |
| Cellular Localization | Mitochondrion outer membrane; Single-pass membrane protein |
| Entrez Gene | 54471 |
|---|---|
| Nucleotide Accession | NP_061881.2 |
Application
SMCR7L Antibody (N-term) western blot analysis in mouse liver tissue lysates (15ug/lane).This demonstrates the SMCR7L antibody detected SMCR7L protein (arrow).| Application Notes | WB:1:100~500 |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
